GluR7/GRIK3 Antibody (2914A) [Alexa Fluor™ Plus 405]

• Reactivity: Hu
• Clone: 2914A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor Plus 405

GluR7/GRIK3 Antibody (2914A) [Alexa Fluor™ Plus 405] Summary

• Specificity: Detects human GluR7/GRIK3 in direct ELISA.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for GluR7/GRIK3 Antibody (2914A) [Alexa Fluor™ Plus 405]

• EAA5
• Excitatory amino acid receptor 5
• GLR7
• GluK3
• GluR7
• gluR-7
• GluR7a
• GLUR7dJ1090M5.1 (glutamate receptor, ionotropic, kainate 3 (GLUR7))
• Glutamate receptor 7
• glutamate receptor, ionotropic kainate 3
• glutamate receptor, ionotropic, kainate 3
• GRIK3

Background

GluR7 is a receptor for glutamate.  Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain. This gene can co-assemble with GRIK4 or GRIK5 to form heteromeric receptors. GluR7 is one of the five subtypes of kainate receptors.  Kainate receptors are widely expressed in the CNS and are involved in the regulation of transmitter release, synapse formation, and in the pathophysiology of brain diseases.  Genetic variants in the GluR7 gene are associated with schizophrenia, major depression, and bipolar disorder.

1. Entrez Gene: GRIK3 glutamate receptor, ionotropic, kainate 3.
2. Matute C. "Therapeutic Potential of Kainate Receptors". CNS Neuroscience & Therapeutics. 2011 Dec; 17(6):661.
3. Begni S, Popoli M, Moraschi S, Bignotti S, Tura G.B, Gennarelli M., "Association Between the Ionotropic Glutamate Receptor Kainate 3 (GRI3) Ser310Ala Polymorphism and Schizophrenia". Mol Psychiatry. 2002; 7(4):416.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.